BioSpace News Archive

Business

BigHat Biosciences Announces Research Collaboration with Merck

BigHat Biosciences, Inc. today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs.

November 29, 2022
·
2 min read
Business

Microbiotica Announces Transition of Leadership

Microbiotica announces a change of leadership as Mike Romanos hands over the Microbiotica CEO role to current COO, Tim Sharpington.

November 29, 2022
·
4 min read
Deals

Amulet Capital Partners Acquires United Vein & Vascular Centers

Amulet Capital Partners, LP today announced that it has acquired United Vein & Vascular Centers (“UVVC” or the “Company”), a leading provider of high-quality vascular care treatment services.

November 29, 2022
·
4 min read
Drug Development

Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting Treatment for Acute Depressive Disorders

Gate Neurosciences today announced that the first cohort of subjects has been dosed in its Phase 1 biomarker and multiple ascending dose study of apimostinel, the company’s 2nd generation rapid-acting injectable NMDAR modulator program.

November 29, 2022
·
3 min read
Business

T-Heart Appoints Sarah Sorrel as Independent Board Member

T-Heart today announced it has appointed Sarah Sorrel as its first independent member of the Board of Directors.

November 29, 2022
·
3 min read
Biotech Beach

Interim Data from Ambrx’s Study of ARX788 selected for Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium

Ambrx Biopharma Inc., or Ambrx announced that interim data from its safety and efficacy study of ARX788 have been selected for a Spotlight Poster Discussion at the 2022 San Antonio Breast Cancer Symposium being held December 6th to 10th, 2022, in San Antonio, TX.

November 29, 2022
·
4 min read
Business

ProSomnus Reports Third Quarter Financial Results and Provides Corporate Update

ProSomnus (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (“OSA”), today announced results for the third quarter ended September 30, 2022 and provided a business update.

November 29, 2022
·
13 min read
BioCapital

Fors Marsh to Include the PreTRM® Test in Its Employee Maternity Benefits Package in Collaboration With Sera Prognostics

Sera Prognostics Inc. and Fors Marsh are collaborating to provide Sera’s PreTRM® Test to employees at Fors Marsh as part of their maternity benefits, effective January 1, 2023.

November 29, 2022
·
7 min read
Business

Zymeworks Announces Expiration of Hart-Scott-Rodino Waiting Period for Zanidatamab License Agreement with Jazz Pharmaceuticals

Zymeworks Inc. today announced that the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976, as amended, for the previously announced license agreement of zanidatamab, a HER2-targeted bispecific antibody, with Jazz Pharmaceuticals has expired.

November 29, 2022
·
5 min read
Biotech Beach

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

Longboard Pharmaceuticals, Inc. today announced that it will present data for LP352, a novel, highly selective investigational treatment in development for seizures associated with a range of developmental and epileptic encephalopathies (DEEs), in two poster sessions at the 2022 AES Annual Meeting.

November 29, 2022
·
4 min read